Daunorubicin

An anthracycline antibiotic used in cancer treatment

Daunorubicin
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Daunorubicin, also known as daunomycin, is an anthracycline antibiotic that is primarily used in the treatment of certain types of cancer, including acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). It is a chemotherapy agent that works by intercalating DNA, thereby inhibiting the synthesis of nucleic acids and inducing apoptosis in rapidly dividing cells.

Mechanism of Action

Daunorubicin exerts its effects by intercalating between base pairs in the DNA helix, thereby disrupting the function of topoisomerase II, an enzyme critical for DNA replication and repair. This interference prevents the proper unwinding of DNA, leading to breaks in the DNA strands and ultimately triggering cell death. Additionally, daunorubicin generates free radicals that cause further damage to cellular components.

Clinical Uses

Daunorubicin is primarily used in the treatment of:

• Acute myeloid leukemia (AML)
• Acute lymphoblastic leukemia (ALL)

It is often used in combination with other chemotherapeutic agents, such as cytarabine, to enhance its efficacy. The drug is administered intravenously, allowing it to rapidly reach systemic circulation and target cancerous cells throughout the body.

Side Effects

The use of daunorubicin is associated with several side effects, which can vary in severity. Common side effects include:

• Myelosuppression, leading to decreased production of blood cells
• Nausea and vomiting
• Alopecia (hair loss)
• Cardiotoxicity, which can lead to congestive heart failure

Due to its potential to cause cardiotoxicity, the cumulative dose of daunorubicin is carefully monitored, and patients may undergo regular cardiac evaluations during treatment.

Pharmacokinetics

Daunorubicin is metabolized primarily in the liver and is excreted in the bile and urine. Its half-life is approximately 18.5 hours, allowing for effective dosing schedules in chemotherapy regimens. The drug's lipophilic nature facilitates its penetration into tissues, including the central nervous system, although its efficacy in treating central nervous system leukemia is limited.

History

Daunorubicin was first isolated from the bacterium Streptomyces peucetius in the 1960s. It was one of the first anthracyclines to be used in clinical practice and paved the way for the development of other related compounds, such as doxorubicin.

Related pages

• Doxorubicin
• Chemotherapy
• Leukemia
• Antibiotics

Daunorubicin

• 
  Daunorubicin 2D Structure
• 
  Daunorubicin Ball-and-Stick Model